drugset / Trial / NCT01614756
A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to determine safety and tolerability of IL-31 mAB
Timeline
- Start
- 2012-07
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-981164 | Monoclonal antibody | 0.01 mg/kg | Subcutaneous |
| Subject | BMS-981164 | Monoclonal antibody | 0.03 mg/kg | Subcutaneous |
| Subject | BMS-981164 | Monoclonal antibody | 0.06 mg/kg | Subcutaneous |
| Subject | BMS-981164 | Monoclonal antibody | 0.1 mg/kg | Subcutaneous |
| Subject | BMS-981164 | Monoclonal antibody | 0.3 mg/kg | Subcutaneous |
| Subject | BMS-981164 | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | BMS-981164 | Monoclonal antibody | 3 mg/kg | Subcutaneous |
| Subject | BMS-981164 | Monoclonal antibody | 10 mg/kg | Subcutaneous |